Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival
2016 (English)In: Oncoimmunology, ISSN 2162-4011, E-ISSN 2162-402X, Vol. 5, no 6, e1154250Article in journal (Refereed) PublishedText
Kings Coll London, Div Canc Studies, Canc Epidemiol Grp, London, England.;Gadjah Mada Univ, Fac Med, Div Hematol Oncol, Yogyakarta, Indonesia..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Endocrine Surgery. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center. Kings Coll London, Div Canc Studies, Canc Epidemiol Grp, London, England..
Kings Coll London, Div Canc Studies, Canc Epidemiol Grp, London, England.;Reg Canc Ctr, Uppsala, Sweden..
Karagiannis, Sophia N.
Kings Coll London, Guys & St Thomass Hosp, NIHR Biomed Res Ctr, St Johns Inst Dermatol,Div Genet & Mol Med,Fac Li, London, England.;Kings Coll London, London, England..
Prior findings linking allergy and cancer have been inconsistent, which may be driven by diverse assessment methods. We used serum specific immunoglobulin E (IgE) against common inhalant allergens that was assessed prior to cancer diagnosis in studying this association. We selected 8,727 Swedish men and women who had measurements of serum allergen-specific IgE and total IgE between 1992 and 1996. Multivariable Cox regression using age as a timescale was performed to assess the associations of IgE sensitization, defined by any levels of serum specific IgE >= 35 kU/L, with risk of overall and specific cancers. A test for trend was performed by assigning scores derived from allergen-specific IgE levels at baseline as an ordinal scale. Kaplan-Meier curves and log-rank test were used to assess cancer survival by IgE sensitization status. During a mean follow-up of 16 year, 689 persons were diagnosed with cancer. We found an inverse association between IgE sensitization and cancer risk, with a hazard ratio (HR) of 0.83 and 95% confidence intervals (CI) of 0.70-0.99. A similar trend was seen with specific IgE scores overall (P-trend = 0.007) and in women (P-trend = 0.01). Although IgE sensitization was not associated with risk of common site-specific cancers, serum specific IgE scores were inversely associated with melanoma risk in men and women combined, and with risk of female breast and gynecological cancers combined. No association with survival was observed. The association between circulating IgE levels and incident cancer may point toward a role of T-helper 2 (T(H)2)-biased response in development of some cancers.
Place, publisher, year, edition, pages
2016. Vol. 5, no 6, e1154250
Allergy, atopy, cancer, immunoglobulin E, cohort
Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-300102DOI: 10.1080/2162402X.2016.1154250ISI: 000379162700021OAI: oai:DiVA.org:uu-300102DiVA: diva2:950819
FunderEU, European Research Council